GSK dropped up to just over $1 billion to buy SiranBio, a Chinese RNA developer, landing rights to SA030: a long-acting siRNA therapy targeting the ALK7 receptor, currently in Phase 1.
No per-share price was disclosed. The deal covers an upfront payment plus development, regulatory, and commercial milestones, with SiranBio keeping tiered royalties on sales outside greater China. The structure closely mirrors GSK’s May 2025 pick-up of efimosfermin alfa from Boston Pharmaceuticals: $1.2 billion upfront plus up to $800 million in milestones for a Phase III-ready FGF21 analog for MASH.
What does GSK actually get? SA030 targets ALK7, a receptor shown in animal models to govern metabolic pathways including sugar control and fat regulation. SiranBio claims the molecule can lower abdominal fat while preserving lean mass, improve insulin sensitivity and blood lipid levels, and cut fat cell-related inflammation, all without touching the GLP-1 pathway. SiranBio carries SA030 through Phase 1, then hands the asset to GSK.
That GLP-1 avoidance is deliberate. CEO Luke Miels told reporters in February the GLP-1 space is “going to be very crowded.” GSK’s cardiometabolic strategy focuses on downstream comorbidities: the fatty liver, fibrosis, and cardiovascular damage that compound after years of obesity. SiranBio has flagged SA030 as a potential combination partner for GLP-1 drugs, which means GSK doesn’t have to beat GLP-1 to profit alongside it.
SiranBio carries the Phase 1 burden. Then it’s GSK’s problem — and GSK’s upside.
— Diana Kowalski